Beone Medicines revenue and financials
Secondary listing. The primary listing is BeOne Medicines · NASDAQ (USD)
$217.00Change from previous close: −1.63%Absolute change: −$3.60
In the fiscal year ended December 2025, Beone Medicines reported revenue of $5.34B (+40.23% year over year). Net income was $286.93M, a net margin of 5.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +40.23%
- 2025 vs 2024
- Net margin
- 5.4%
- 2024: -16.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 1,705 | 1,513 | 1,498 | 1,412 | 1,315 | — |
| Cost of revenue | 175 | 167 | 142 | 197 | 165 | — |
| Gross profit | 1,531 | 1,346 | 1,356 | 1,216 | 1,151 | — |
| Selling, general and administrative | 593 | 555 | 555 | 529 | 538 | — |
| Research and development | 612 | 541 | 615 | 524 | 525 | — |
| Operating income | 325 | 250 | 185 | 163 | 87.9 | — |
| EBIT | 352 | 292 | 213 | 163 | 108 | — |
| EBITDA | 393 | 333 | 249 | 200 | 143 | — |
| Interest expense | 39.7 | 32.9 | — | — | 8.0 | 7.0 |
| Pre-tax income | 312 | 259 | 149 | 147 | 99.5 | — |
| Income tax | 75.5 | 31.9 | 82.7 | 22.3 | 5.2 | — |
| Net income | 237 | 227 | 66.5 | 125 | 94.3 | — |
| Net income to common shareholders | 237 | 227 | 66.5 | 125 | 94.3 | — |
| Basic EPS | 0.16 | 0.16 | 0.05 | — | 0.07 | 0.00 |
| Diluted EPS | 0.16 | 0.15 | 0.04 | — | 0.06 | 0.00 |
| Average shares (basic) | 1,450 | 1,442 | 1,439 | — | 1,408 | 1,390 |
| Average shares (diluted) | 1,505 | 1,505 | 1,500 | — | 1,463 | 1,445 |